[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cytology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cytology":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100586142","application-of-endoscell-intraoperative-cellular-probing-technology-for-early-stage-breast-cancer-100586142",false,"NCT06911528","Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer","A Prospective Study to Evaluate the Application of EndoScell Intraoperative Cellular Probing Technology in Breast Conserving Therapy and Sentinel Lymph Node Biopsy for Early-Stage Breast Cancer","EDGE","Inclusion Criteria:\n\n* Age 18 years and older (inclusive)\n* Female\n* Preoperative pathology confirmed invasive breast carcinoma or ductal carcinoma in situ\n* Scheduled for sentinel lymph node biopsy\n* Capable of and willing to provide informed consent\n\nExclusion Criteria:\n\n* Patients with a confirmed allergy to methylene blue or sodium citrate tracers\n* Pregnant or lactating women\n* Patients unwilling to participate in the clinical study","FEMALE","18 Years",{"count":20,"type":21},709,"ESTIMATED","INTERVENTIONAL",[24],"NA","Sentinel Lymph Node Biopsy (SLNB) is a common surgical treatment for breast cancer and a primary method for assessing the pathological status of axillary lymph nodes. Precise intraoperative detection of sentinel lymph nodes during surgery assists in timely evaluation of axillary lymph node pathology and helps in formulating further treatment strategies.\n\nTouch imprint cytology (TIC) is one of the most commonly used intraoperative detection techniques. The new intraoperative cellular detection technology, EndoScell Scanner (ES), uses an improved real-time miniaturized fluorescence microscopy system for image acquisition. The ultra-high-resolution images obtained can reach the cellular level. In previous studies, the accuracy and sensitivity of this technology for intraoperative detection of sentinel lymph nodes were comparable to imprint cytology, but it is much more rapid. The detection technology uses fluorescein sodium and methylene blue as fluorescent dyes, which is non-invasive and also non-consumptive of tissue samples.\n\nThis study involves patients scheduled for sentinel lymph node biopsy and aims to evaluate the clinical application value of the EndoScell Scanner (ES) for intraoperative assessment of the pathological status of sentinel lymph nodes through a prospective self-controlled study. To avoid the potential impact of methylene blue on the ES detection technology, we will use mitoxantrone as a new dye for sentinel lymph node tracing in this study.\n\nThe primary study objective is to compare the accuracy of the ES detection technology in assessing sentinel lymph node status, using paraffin pathology examination as the gold standard. The primary endpoint is the accuracy of the ES technology. Secondary endpoints include the image quality score of the ES detection, the learning curve of the surgeons, and the time required for detection.",[27,28,29,30],"Breast Cancer","Sentinel Lymph Node","Frozen Section","Cytology",[32,33,34,35,36],"Breast carcinoma","sentinel lymph node","tracer","touch imprint cytology","epifluorescence widefield microscope system","RECRUITING","2025-03-28",{"date":40,"type":41},"2025-04-04","ACTUAL",{"date":43,"type":41},"2024-01-30",{"date":45,"type":21},"2025-12-31",{"name":47,"class":48},"Fudan University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":69,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100567757","clinical-studies-of-endometrial-cytology-and-cervical-methylation-assays-in-endometrial-cancer-screening-and-fertility-preservation-evaluation-100567757","NCT06672341","Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation Evaluation","A Prospective, Open, Observational Clinical Study on Endometrial Cytology and Cervical Methylation Testing for Screening and Evaluating Fertility-Sparing Treatment in Endometrial Cancer","Inclusion Criteria:\n\n* Participants must meet all of the following criteria to be eligible for the study:\n\n  1. Color Doppler ultrasound indicating intrauterine masses or abnormal endometrial thickening (for postmenopausal women not receiving hormone replacement therapy, endometrial thickness \\>5mm).\n  2. Patients undergoing follow-up and efficacy evaluation for fertility-sparing treatment of endometrial cancer or atypical endometrial hyperplasia.\n  3. Patients with endometrial thickening following endocrine therapy for breast cancer.\n  4. Signed informed consent form.\n  5. Good compliance.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  1. Diagnosed with cervical cancer.\n  2. Severe systemic complications preventing hysteroscopy.\n  3. Pregnant or recent history of miscarriage.\n  4. Acute genital tract infection or pelvic inflammatory disease.\n  5. Insertion of an intrauterine device.\n  6. Sexual activity, vaginal douching, or medication use within 24 hours.",{"count":58,"type":21},200,"1 Year","OBSERVATIONAL","The current study aims to assess high-risk patients using both liquid-based cytology and cervical methylation testing. The results will be compared with the traditional hysteroscopic pathological findings to determine the sensitivity and specificity of these methods for early detection of endometrial cancer, thereby evaluating their potential application in early screening.\n\nPrimary Objectives：\n\n1. To evaluate the sensitivity, specificity, and accuracy of endometrial cytology for screening endometrial cancer.\n2. To assess the sensitivity, specificity, and accuracy of methylation testing for screening endometrial cancer.\n3. To perform further molecular testing on tissue samples obtained from endometrial cytology and cervical methylation tests, aiming to explore early screening-sensitive indicators.\n\nSecondary Objectives：\n\n1. To determine the value of endometrial cytology in evaluating the efficacy of fertility-sparing treatments for endometrial cancer.\n2. To assess the value of methylation testing in evaluating the efficacy of fertility-sparing treatments for endometrial cancer.",[63,64,30,65,66,67,68],"Endometrial Cancer","Methylation","Fertility Preservation","Screening Tool","Liquid Biopsy","Non-invasive",[63,70,71,30,72,73,74,75,76],"screening","methylation","Liquid-Based Cytology Test","Early diagnosis","fertility-sparing","liquid biopsy","non-invasive","NOT_YET_RECRUITING","2024-11-03",{"date":80,"type":41},"2024-11-05",{"date":82,"type":21},"2024-11-04",{"date":84,"type":21},"2026-02-01",{"name":86,"class":48},"Yulan Ren",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":49},"100558963","cervical-cytology-dna-methylation-for-cervical-cancer-screening-100558963","NCT06557954","Cervical Cytology DNA Methylation for Cervical Cancer Screening","Cervical Cytology DNA Methylation for Cervical Cancer Screening: A Real Word Study","Inclusion Criteria:\n\n* Aged 18 years or older\n* With uterine cervix intact\n* Given consents to participate the study\n* With detailed follow-up outcomes\n\nExclusion Criteria:\n\n* Not meeting all of the inclusion criteria",{"count":95,"type":21},30000,"Cervical cancer represents one of the foremost causes of cancer-related morbidity and mortality among women worldwide. Given the current limitations, such as the low specificity of human papillomavirus (HPV) testing and the relatively low sensitivity of cytological examinations, there is a pressing need for a novel, non-invasive, safe, and precise screening method. This study aims to undertake a multicentre, real-world investigation, incorporating at least 10 sub-centres and enrolling 30,000 participants. Histopathological examination results will serve as the 'gold standard' for evaluating the screening efficacy of human PAX1 and JAM3 gene methylation assays (PAX1m\u002FJAM3m), HPV testing, and cytological examinations. Furthermore, the study seeks to elucidate the relationship between DNA methylation levels and persistent HPV infection, while also assessing the applicability of PAX1m\u002FJAM3m across diverse clinical settings. By focusing on alterations in DNA methylation levels within cervical exfoliated cells as the primary research trajectory, this study aspires to furnish novel insights and theoretical foundations for the prevention and management of cervical cancer, targeting PAX1m\u002FJAM3m. The ultimate objective is to facilitate the clinical implementation of an enhanced cervical cancer screening protocol, thereby addressing the deficiencies of current screening methodologies, achieving greater precision in cervical cancer screening, and effectively reducing the incidence of cervical cancer while mitigating the risks of overdiagnosis and overtreatment.",[98,99,30,100,101,102],"Cervical Cancer","DNA Methylation","Human Papillomavirus Infection","Cervical Intraepithelial Neoplasia","Cancer Screening","2024-08-15",{"date":105,"type":41},"2024-08-19",{"date":107,"type":21},"2024-09-01",{"date":109,"type":21},"2026-10-01",{"name":111,"class":48},"Lei Li"]